Toggle light / dark theme

Rapamycin is the gold standard for longevity interventions

It sucks that the primary reason this has not gone forward is because it is off patent.


This video is reproduced from a presentation I gave to the Euro-Geroscience Task Force “Challenges in Developing Geroscience Drug Trials” held March 23, 2022 in Toulouse, France. It gives an introduction to the state of research on rapamycin as a potential longevity and healthspan drug and some of the challenges and opportunities for clinical development.